Epigenetic Biological Age Tests: Who Funded Yale’s Study?

The major Nature Medicine study widely reported as an independent Yale verdict on anti-aging therapies was actually co-authored by employees of TruDiagnostic, a commercial seller of epigenetic biological age tests. Lead Yale researchers also hold patents on DNA methylation clocks licensed directly to TruDiagnostic, the very class of proprietary tests the study validated as responsive to clinical interventions.

Who Funded and Co-Authored the Yale Anti-Aging Study?

Three employees of the commercial testing laboratory TruDiagnostic co-authored the benchmark study alongside Yale School of Medicine researchers who receive consulting fees and patent licensing royalties from the firm.

When news outlets covered the 51-study analysis of human aging interventions, they presented the findings as the work of university scientists acting without commercial skin in the game. A reading of the study’s formal disclosures tells a different story.

According to the Author Affiliations and Competing Interests sections of the Nature Medicine paper (“Responsiveness of epigenetic aging biomarkers to longevity interventions in humans,” DOI: 10.1038/s41591-026-04562-9), three of the 13 co-authors, Ryan Smith, Natàlia Carreras-Gallo, and Varun B. Dwaraka, are employees of TruDiagnostic. Based in Lexington, Kentucky, TruDiagnostic is a private commercial laboratory that sells epigenetic biological age tests directly to consumers, longevity clinics, and clinical trial sponsors.

The commercial ties extend directly to the academic leads at Yale School of Medicine. Lead author Raghav Sehgal and senior author Assistant Professor Albert Higgins-Chen disclose in the paper’s Crossmark competing-interests record that they are named co-inventors on a United States patent for Systems Age. Systems Age is a computer algorithm that estimates biological aging across 11 organ systems by measuring DNA methylation, chemical tags attached to DNA that regulate gene activity without altering the underlying genetic code. That patent is commercially licensed to TruDiagnostic, which markets the test under the brand name SYMPHONYAge.

Beyond the patent license, competing-interests declarations across the Nature Medicine benchmark and the companion Nature Aging Systems Age paper state that Sehgal serves as a scientific advisor to TruDiagnostic and has received consulting fees from both TruDiagnostic and the venture firm LongevityTech.fund. Higgins-Chen reports receiving consulting fees from TruDiagnostic and FOXO Biosciences.

None of these corporate roles are hidden in the scientific literature. They sit in the paper’s back matter, raising a structural question: how did the commercial tests perform when their own inventors and vendors built the scoreboard?

Which “Winning” Clocks Are Patented or Sold by the Authors?

The Nature Medicine study validated newer multi-dimensional DNA methylation clocks, including SYMPHONYAge and OMICmAge, that are patented by the Yale authors or sold commercially inside TruDiagnostic’s $499 to $849 consumer test kits.

In the study, the authors curated a database called TranslAGE across 51 longitudinal human intervention studies, calculating 16 primary epigenetic clocks and 94 additional DNA methylation sub-biomarkers (110 biomarkers in total) to see which metrics shift when patients change their diet, exercise, or take prescription drugs. According to the Nature Medicine dataset, 20 of the 51 studies significantly decreased epigenetic age across multiple biomarkers (13 after multiple-testing correction), 5 increased epigenetic age, and 26 showed no significant effect.

The authors grouped the 16 primary clocks into four categories: Generation 1, Generation 2+, Reliability-optimized (PC clocks), and a newer category they termed “Generation X” (explainable, multi-dimensional clocks), concluding that mortality-trained, pace-of-aging, and explainable Generation X clocks are the most useful for guiding clinical trial endpoints. Cross-referencing the study’s clock panel against TruDiagnostic’s publication and product portfolio shows how closely the evaluated panel tracks the authors’ commercial offerings:

• SYMPHONYAge (Systems Age): Developed at Yale by Sehgal, Higgins-Chen, and Morgan Levine and published in Nature Aging, this Generation X biomarker quantifies aging across 11 physiological systems (such as heart, lung, brain, kidney, and liver). Patented in 2024 and licensed to TruDiagnostic, it is already used in pharmaceutical evaluations, including Eli Lilly’s tirzepatide analyses presented at the 2026 Aging Research and Drug Discovery meeting.
• OMICmAge and DNAmEMRAge: Highlighted alongside Systems Age in the study’s Generation X category, OMICmAge was developed by TruDiagnostic researchers Varun Dwaraka, Natàlia Carreras-Gallo, and Ryan Smith in collaboration with Harvard Medical School’s Jessica Lasky-Su, Sehgal, and Higgins-Chen. Published in Nature Aging (DOI: 10.1038/s43587-026-01073-7), OMICmAge integrates 396 epigenetic biomarker proxies (266 metabolites, 109 proteins, and 21 clinical variables) and was validated in the TruDiagnostic Biobank of 14,213 customers.
• DunedinPACE and PC Clocks: The panel’s top-responding pace-of-aging and reliability-optimized clocks include DunedinPACE, a blood test measuring the rate of biological aging licensed commercially to TruDiagnostic, and Principal Component (PC) clocks developed by Levine and Higgins-Chen to reduce technical noise.

For consumers and clinics, these academic validations translate directly into laboratory revenue. On TruDiagnostic’s online storefront, the standalone TruAge test retails for 499forasinglekit(399.20 with promotional discounting, or $249.50 per test on a four-test annual subscription of $998, while the combined TruAge + TruHealth kit retails for 849pertest(1,698 annually for four tests. Those commercial reports sell OMICmAge, the 11 organ-system ages of SYMPHONYAge, and DunedinPACE as their core diagnostic readouts.

Understanding how a benchmark evaluation for commercial diagnostic clocks turned into viral consumer advice requires looking at how the study was packaged for the press.

Did the Study Actually Prove Which Drugs or Supplements Slow Aging?

No, the study used 51 existing clinical trials as calibration controls to test whether DNA methylation clocks can detect short-term biological shifts, rather than proving whether those therapies extend human lifespan.

Mainstream coverage uniformly reported that Yale scientists used anti-aging blood tests to prove that Mediterranean diets, exercise, metformin, and GLP-1 drugs like semaglutide slow down human aging, while over-the-counter supplements fail. That framing inverted the study’s scientific method.

As detailed in the Nature Medicine analysis, the researchers did not set out to test whether diet, exercise, or prescription metabolic drugs improve long-term health. Instead, they noted that responsiveness is a prerequisite for Food and Drug Administration (FDA) surrogate endpoint qualification, and used 51 trials of hypothesized longevity interventions, ranging from caloric restriction and metformin to folate and omega-3 supplements, as benchmark tests to see which epigenetic clocks consistently detect short-term biological change.

As Sehgal noted in the Yale News press release, the team started from the premise that “we already know that certain things might prolong health span and lifespan” from prior retrospective and animal data, and used those interventions to test whether the blood biomarkers shifted accordingly.

The narrowing of this nuance began with the institutional press materials. Neither the August 21 Yale News release (“Can you slow the aging process? Study reveals which interventions might help”) nor the August 26 Yale School of Medicine feature mentioned TruDiagnostic’s co-authorship, the commercial licensing of Systems Age as SYMPHONYAge, or the authors’ consulting ties. Both institutional articles named only the Yale laboratory collaborators and academic grant funders.

Journalists working from the press release repeated the omission. By presenting the clocks as neutral yardsticks rather than the commercial products under evaluation, coverage missed the downstream regulatory stakes of the paper.

Why Does Commercial Co-Authorship Matter in Biomarker Validation?

When developers co-author studies validating their own diagnostic tests for use as FDA clinical trial endpoints, independent researchers warn of inflated effect sizes and restricted algorithmic access.

In clinical drug development, the primary bottleneck for anti-aging therapies is time: running a trial to see if a drug extends human life takes decades. As the authors state in their opening pages, the goal of mapping biomarker responsiveness is “uncovering DNAm biomarkers that can be used as surrogate aging endpoints”, short-term biological measurements used in place of long-term survival outcomes to guide future clinical trials and minimize study duration.

When the researchers who invent and commercially sell candidate biomarkers co-author the benchmark studies validating them, clinical epidemiologists point to a well-documented structural risk. In a foundational JAMA analysis of biomarker effect sizes, Stanford University methodologist John P. A. Ioannidis and Orestis A. Panagiotou demonstrated that highly cited biomarker validation studies frequently report inflated effect sizes compared with subsequent independent meta-analyses, while diagnostic researchers have warned that biomarker prioritization is routinely skewed by commercial considerations.

In epigenetic testing, that commercial tension is magnified by technical noise. According to an independent analysis by Longevity Science Daily and the Yale lab’s own companion reliability study in Aging Cell (DOI: 10.1111/acel.70635), running traditional epigenetic clocks twice on the exact same blood DNA sample can yield results that differ by a median of 0.9 to 2.4 years and a maximum of 4.5 to 8.6 years, a technical swing larger than the 1- to 3-year changes reported in most clinical intervention trials. Proving that newer clocks overcome that noise is essential to selling them to trial sponsors.

A second test of independence in biomarker benchmarking is whether outside scientists can audit and run the winning algorithms themselves without paying the commercial vendor. Here, the open-source record is split between the Yale-developed clocks and TruDiagnostic’s in-house clock:

• Open-Source Yale Clocks: In the Higgins-Chen Lab GitHub repository, the open-source R package methylCIPHER (used in the Nature Medicine paper to calculate the 110+ biomarkers) publicly provides the code to compute PC-Clocks, CausalAge, DunedinPACE, and Yale’s Systems Age.
• Closed Commercial Software for OMICmAge: By contrast, the Code Availability statement in the Nature Aging OMICmAge paper states that “Code to calculate all metrics is accessible via TruDiagnostic’s DNAm Analysis Software,” with underlying clinical and multi-omic training data restricted due to participant consent.

How Do the Authors Defend the Study’s Independence?

The authors disclosed all financial ties in the Nature Medicine paper, applied identical statistical rules across 16 competing academic clocks, and relied on TruDiagnostic’s private cohorts to assemble a 51-study dataset unavailable in public archives.

Every corporate affiliation, patent filing, and consulting arrangement held by Sehgal, Higgins-Chen, and their TruDiagnostic co-authors was declared in the Nature Medicine publication in compliance with Springer Nature’s ethics policies.

From a methodological standpoint, the authors’ strongest defense rests on the scale and standardization of their analytical pipeline. Rather than testing only their own algorithms on a single cohort, the team evaluated 16 clocks, including competing models built by independent academic groups such as Horvath1, Horvath2, Hannum, PhenoAge, and GrimAgeV2, using uniform age-residual normalization and paired t-tests across 51 independent studies.

To guard against single-clock flukes, the authors established a two-part statistical rule in the Nature Medicine paper: an intervention was only classified as having a “bona fide” effect if it shifted multiple biomarkers of a given generation in the same direction within a study (Rule 1) and replicated that shift across a second independent study of the same intervention (Rule 2).

There is also a logistical reason academic longevity labs partner with commercial testing providers. As the paper’s methods section details, assembling the 51-study TranslAGE database required combining public repositories, the National Center for Biotechnology Information’s Gene Expression Omnibus (GEO) and the European Molecular Biology Laboratory (EMBL), with private interventional cohorts sequenced and stored in TruDiagnostic’s proprietary repository. Without TruDiagnostic’s private clinical trial datasets and standardized Illumina methylation array processing, a 51-study human benchmark could not have been assembled from public academic archives alone.

Yet as pharmaceutical sponsors and clinical investigators use the TranslAGE roadmap to select which biological age tests to buy for upcoming Phase 2 trials, the dual role of the study’s authors, serving simultaneously as the referees of epigenetic clocks and the patent-holders and commercial vendors of the winning assays, will shape which anti-aging drugs get funded, and who collects the fees for measuring them.

Frequently Asked Questions

Was the Yale anti-aging study funded or conducted independently of biological age test companies?

No. While mainstream media described the Nature Medicine study solely as an independent Yale discovery, three of its 13 co-authors are employees of the commercial testing lab TruDiagnostic, and lead Yale authors Raghav Sehgal and Albert Higgins-Chen receive consulting fees and patent licensing royalties from the company.

Which commercial biological age tests are linked to the Yale researchers?

Lead Yale researchers Raghav Sehgal and Albert Higgins-Chen co-invented the patented Systems Age algorithm, which TruDiagnostic licenses and sells commercially as SYMPHONYAge inside its $499 TruAge and $849 TruAge + TruHealth test kits. They also collaborated with TruDiagnostic employees to develop OMICmAge, another flagship biomarker evaluated in the study.

Can independent scientists verify the calculations behind the clocks evaluated in the study?

Only partially. While the Yale lab’s open-source methylCIPHER software on GitHub includes public code to compute Systems Age, DunedinPACE, and Principal Component clocks, the Nature Aging code availability statement notes that the code to calculate TruDiagnostic’s OMICmAge is restricted to TruDiagnostic’s proprietary DNAm Analysis Software.

How accurate are repeated epigenetic biological age tests on the same blood sample?

According to a companion study by the Yale team published in Aging Cell, running traditional epigenetic clocks twice on the exact same blood DNA sample can yield results differing by a median of 0.9 to 2.4 years and up to 8.6 years, a technical margin of error larger than the 1- to 3-year changes reported in most clinical intervention trials.